In an era of heightened regulatory scrutiny, clinical evaluation report writing has become a cornerstone of medical device compliance for manufacturers operating in the United States and European Union. Regulatory authorities increasingly expect clear, well-documented clinical evidence demonstrating that a device is safe, performs as intended, and delivers measurable clinical benefit. Understanding what a Clinical Evaluation Report (CER) is—and how FDA and EU MDR expectations differ—is critical to avoiding costly regulatory delays and non-compliance findings.
This blog explains the purpose, structure, and regulatory expectations of a Clinical Evaluation Report, with practical insights tailored for global medical device and digital health companies.
A Clinical Evaluation Report is a structured regulatory document that systematically collects, appraises, and analyzes clinical data related to a medical device. Its primary objective is to demonstrate that the device meets applicable safety and performance requirements when used according to its intended purpose.
Under the EU Medical Device Regulation (MDR), the Clinical Evaluation Report is a required and integral part of a manufacturer’s technical documentation. In contrast, while the US FDA does not explicitly require a document labeled as a “CER,” the underlying clinical evaluation principles are embedded within FDA premarket and post-market review processes.
Regardless of geography, the CER serves as a scientific and regulatory justification for placing and maintaining a medical device on the market.
Under EU MDR Article 61 and Annex XIV, manufacturers must conduct and document a clinical evaluation for all medical devices, regardless of class. The regulation emphasizes:
Notified Bodies review CERs in detail, making them one of the most frequently cited sources of non-conformities during conformity assessments.
In the US, the FDA evaluates clinical evidence as part of regulatory submissions such as:
Although the FDA does not require a standalone CER, manufacturers often prepare CER-style documentation internally to support regulatory strategy, risk assessment, and benefit–risk justification.
While both regulatory systems prioritize patient safety, their approaches differ:
Understanding these differences is essential for companies pursuing dual-market approvals.
Clinical data may be required in both regions depending on:
Acceptable clinical data sources include published literature, clinical investigations, registries, real-world evidence, and post-market surveillance data. Regulators expect manufacturers to justify the relevance, quality, and sufficiency of all clinical data used.
A compliant Clinical Evaluation Report typically includes:
Each element must be consistent with the device’s risk management file, usability engineering, and quality management system documentation.
A common misconception is that a CER is the same as a clinical study. In reality:
Clinical investigations may be required when existing evidence is insufficient. Results from clinical studies are then incorporated into the CER to support regulatory conclusions.
Regulatory reviewers frequently identify deficiencies such as:
Many of these issues arise when manufacturers treat CERs as static documents rather than living regulatory tools.
Update frequency depends on device classification and risk:
Class I and Class IIa devices: Clinical Evaluation Reports should be reviewed and updated at defined intervals or whenever significant design, clinical, or safety changes occur.
Class IIb and Class III devices: CERs should be updated at least annually or in alignment with Periodic Safety Update Report (PSUR) review cycles.
Trigger events include design modifications, safety signals, new clinical data, regulatory changes, or increased adverse event trends.
A proactive update strategy significantly reduces regulatory risk.
To ensure robust compliance:
Many manufacturers now adopt integrated clinical evaluation plan & report writing approaches to ensure consistency between planning, execution, and regulatory documentation.
A clear understanding of Clinical Evaluation Report expectations under both FDA and EU MDR frameworks enables medical device and digital health companies to reduce regulatory uncertainty, accelerate approvals, and maintain long-term compliance. By investing in structured processes, high-quality evidence appraisal, and expert-led clinical evaluation report writing, manufacturers can confidently meet global regulatory demands while supporting patient safety and innovation.
A Clinical Evaluation Report (CER) demonstrates that a medical device is safe, performs as intended, and delivers clinical benefit throughout its lifecycle. It provides regulators with structured clinical evidence supporting conformity with EU MDR and FDA regulatory expectations.
Yes. Under EU MDR Article 61 and Annex XIV, all medical devices must undergo clinical evaluation, and the results must be documented in a Clinical Evaluation Report. The depth of the CER depends on device classification, risk, and available clinical evidence.
The FDA does not require a standalone document called a “CER.” However, clinical evaluation principles are embedded in FDA submissions such as 510(k), De Novo, and PMA. Many manufacturers prepare CER-style documentation to support benefit–risk assessment and regulatory strategy.
CER updates depend on device risk:
Class I & IIa devices should be reviewed periodically or when significant changes occur.
Class IIb & III devices should be updated at least annually or aligned with PSUR cycles.
Updates are also triggered by new clinical data, safety signals, or regulatory changes.
Acceptable clinical data sources include published scientific literature, clinical investigations, registries, real-world evidence, post-market surveillance data, and PMCF studies. All data must be critically appraised for relevance, quality, and validity.
At PM Consultants we are a group of dedicated medical writers, regulatory affairs professionals, clinical researchers, and quality
© 2025 Developed By Omx Technologies
